FDA panel votes to add peptides to permitted compounding list despite opposition from agency scientists

FDA panel votes to add peptides: Peptides Gain Entry to Compounding List After FDA Committee Deliberation Provpnadvice.com – On Thursday, a significant

Peptides Gain Entry to Compounding List After FDA Committee Deliberation

Provpnadvice.com – On Thursday, a significant shift occurred within the Food and Drug Administration’s regulatory framework as the committee responsible for compounded medications voted to include several peptide compounds on the permitted substances list. This decision came despite notable resistance from agency scientists who had previously expressed doubts about the scientific foundation supporting these compounds.

The Committee’s Deliberation Process

The FDA’s Pharmacy Compounding Advisory Committee convened to evaluate public input and review presentations from agency personnel regarding four specific peptides: BPC-157, KPV, TB-500, and MOTS-c. Industry advocates have promoted these compounds for addressing various health concerns, including ulcerative colitis, wound healing, obesity, and osteoporosis.

The committee’s primary responsibility involved determining whether these peptides warranted inclusion on the 503A bulks list, which designates substances that compounding pharmacies operating under section 503A regulations may manufacture and distribute directly to consumers.

By 7 p.m. EDT on Thursday, the committee reached a decision regarding three of the four peptides. The vote resulted in eight members supporting inclusion, six opposing it, and one member choosing to abstain from voting. BPC-157, KPV, and TB-500 all received favorable consideration. Meanwhile, deliberations regarding MOTS-c continued as the meeting progressed.

Conflicting Perspectives on Evidence

Opposition to the proposed additions centered on insufficient data demonstrating both safety and therapeutic effectiveness. Conversely, proponents maintained that the absence of disproof constituted adequate justification for inclusion.

Before the committee meeting commenced, FDA scientists prepared briefing documentation indicating that all four peptides under consideration lacked sufficient evidentiary support to confirm their safety and efficacy for their intended applications. Agency representatives reinforced this position during Thursday’s proceedings.

One staff member highlighted standardization challenges, noting that the FDA had encountered numerous products marketed under identical names yet containing different active ingredients. For instance, multiple substances bearing the designation “BPC-157” contained varying molecular compositions.

“Inconsistent naming conventions can contribute to the BDS being not well characterized because there is no basis for a long-term understanding of the composition of the BDS,” the staffer explained in their presentation, referring to bulk drug substances.

“There is no basis for an expectation that the common name will always identify the same BDS, the same specific chemical form and structure,” the representative added.

Market Dynamics and Consumer Protection

Advocates for inclusion emphasized that formal recognition would channel consumers away from unregulated markets. Many purchasers currently obtain so-called “research-grade” peptides from international online vendors without quality assurance mechanisms.

“Just last week, I had a patient whose research grade whatever that they got from someplace that they brought to me to fix was laced with MDMA and ecstasy. That’s not protecting the American people,” PCAC member Melissa Loseke stated while explaining her affirmative vote.

Asare Christian, a PCAC member who operates clinics providing peptide therapies, defended the committee’s direction.

“We are always taking risks with patients with all the interventions we do as physicians. And this provides an avenue, an alternative, to support the already existing available tools that we have to take care of patients.”

Continued Skepticism Among Committee Members

Not all members shared the optimistic outlook. Several committee participants aligned with FDA scientists’ positions, maintaining that current evidence remained inadequate for widespread compounding availability.

During the initial consideration of BPC-157, committee members Elizabeth Rebello, Brian Serumaga, and Josh Mailman expressed reservations about insufficient efficacy demonstrations.

Brian Lee, associate professor of medicine at the Keck School of Medicine of USC, cautioned that while Thursday’s outcome did not constitute formal FDA approval, consumers would likely interpret it as such.

“I think that the data that we do have, the existing randomized data, is showing that BPC-157 may be no better than placebo,” Lee observed. “And knowing that most important, serious safety events like liver damage, where there is potential concern here, aren’t detected by self-report. So, I think this endorsement can be potentially harmful, and it cannot in good conscience vote yes.”

The committee’s decision reflects an ongoing tension between regulatory caution and industry demands for expanded therapeutic options through compounding pharmacies.